Castle Biosciences (CSTL) Assets (2018 - 2026)

Castle Biosciences has disclosed Assets across 9 years of filings, most recently posting $547.8 million for Q1 2026.

• Assets for Q1 2026 came in at $547.8 million, up 9.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $547.8 million (up 9.19% YoY), and the FY2025 annual result was $578.6 million, up 8.91% from the prior year.
• Assets came in at $547.8 million for Q1 2026 at Castle Biosciences, down from $578.6 million in the prior quarter.
• In the past five years, Assets ranged from a high of $578.6 million in Q4 2025 to a low of $425.4 million in Q2 2023.
• The 5-year median for Assets is $458.5 million (2024), against an average of $486.9 million.
• Across the five-year window, Assets retreated 7.19% in 2023 and rose 18.01% in 2024, its largest moves.
• Castle Biosciences' Assets stood at $447.3 million in 2022, then gained by 1.34% to $453.3 million in 2023, then climbed by 17.18% to $531.2 million in 2024, then rose by 8.91% to $578.6 million in 2025, then decreased by 5.32% to $547.8 million in 2026.
• The last three Assets figures came in at $547.8 million (Q1 2026), $578.6 million (Q4 2025), and $562.8 million (Q3 2025), per Business Quant data.